Janssen Signs a Research Agreement with TenNor to Develop Treatments for Nontuberculous Mycobacteria Diseases

 Janssen Signs a Research Agreement with TenNor to Develop Treatments for Nontuberculous Mycobacteria Diseases

Janssen Signs a Research Agreement with TenNor to Develop Treatments for Nontuberculous Mycobacteria Diseases

Shots:

  • The companies plan to leverage TenNor’s multitargeting drug conjugation platform to discover new therapies for NTM diseases. The agreement was facilitated by J&J
  • The focus of the pact to discover and develop novel therapies for NTM diseases with the potential to shorten the duration of treatment with better safety and efficacy
  • The collaboration builds on the scientific know-how and background IP of TenNor associated with its drug conjugation technology. The collaboration will integrate companies’ expertise together to discover new treatment modalities for NTM diseases

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Web24 News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post